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Introduction 
This Second International Workshop on Hand Osteoar- 
thritis (OA) stems from the outstanding success of the first 
workshop held in Marbella, Spain in 1994, which left many 
questions unanswered and gave rise to several more. The 
publication of its proceedings was a tremendous success, 
reflecting a wide interest in the rheumatology and scientific 
communities and a desire to learn more about this disease. 
In fact, one of the conclusions that emerged from the 
meeting was that much remained to be learned about hand 
OA. There is still a world to discover with regard to many 
aspects of the disease. The principal aim is to better define 
the disease per se, providing essential information to 
clinicians to allow for better means of evaluating the clinical 
symptoms and their impact on the quality of life and of 
measuring the progression of the disease. On one hand, 
specific new tools are probably needed for targeting a 
'narrow' model of hand OA. On the other hand, it seems 
necessary to broaden the debate in order to expand our 
knowledge of the epidemiology, genetics and risk factors so 
as to establish a more rational classification and to improve 
our global understanding of the disease in the context of 
generalized OA. 
The increasing demand for the development of new and 
more effective drugs for the symptomatic and hopefully 
curative treatment of OA and hand OA is a very strong 
incentive to improve the existing imaging techniques and 
develop new ones that could accurately and reproducibly 
measure the progression of the disease. The development 
of validated methods to clinically assess the efficacy of 
therapeutics over time is necessary and essential for the 
conduct of clinical trials. 
We are pleased to bring you the most significant papers 
presented at this workshop, which we believe will fulfill 
many of the anticipations and address several questions 
that arose from the first workshop. This atelier was one 
more step in the process of learning about a very fascinat- 
ing disease, which with the aging of the world population 
touches an increasing number of people. The main objec- 
tives are to review the most recent data on the disease and 
to organize a forum that will allow for an interactive discus- 
sion between the participants and experts in the field, so as 
to bring consensus and propose new perspectives on many 
of the topics previously presented. We hope that this 
workshop will contribute to improving our knowledge and 
understanding of OA. 
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